Solventum Corporation

Read together, the filings show a company with flat top-line results, a sharp rebound in reported profit, and a cash conversion problem that the headline earnings figures do not reveal. The Beneish M-Score for 2025 is -2.069, which is below -1.78 and therefore not in the elevated manipulation-risk zone. This is a screening model that compares several financial ratios across years; a value below the threshold means it did not raise a flag, not that the reported numbers have been verified. The Altman Z″-Score is 2.34, in the grey zone between 1.10 and 2.60, which signals moderate financial strength rather than clear safety or clear distress. The Piotroski F-Score is 6 of 8 computable signals, meaning six of the eight tests that could be computed from the data passed; it is a checklist of profitability, leverage, and efficiency tests. The Fog Index is not in the data, so the readability of the MD&A is not assessed here. Management's Q1 2026 10-Q narrative centers on capital return: the repurchase table covers 922,636 shares in the quarter and the remaining capacity under the $1.0 billion program. Repurchases are a use of cash, so the weak 2025 operating cash flow of $369 million matters for how much capacity the company has to fund them from operations. The 10-K risk factors describe regulation by the FDA under its device classes and drug pathways (NDA and OTC monograph), the EU Medical Device Regulation, and China's NMPA, and state that none of the medical devices in the U.S. portfolio are Class III. These exposures apply mainly to the MedSurg and Dental Solutions segments, while Health Information Systems products do not meet the definition of medical devices or pharmaceuticals. Readers may want to look at the 2025 segment results and the cash flow statement to see whether the profit recovery is tied to operations or to items the excerpts do not show.

Catalyst.According to the MD&A and recent results, the business is growing slowly but earning more at the operating line. Revenues reached $8.32 billion in 2025, up 0.9% from $8.25 billion in 2024, while operating income rose to $2.18 billion from $1.04 billion. Net income reached $1.56 billion compared with $479 million a year earlier. The risk factors name three segments: MedSurg, Dental Solutions, and Health Information Systems. In the first quarter of 2026, Solventum repurchased 922,636 shares under a board program approved in November 2025 that authorizes up to $1.0 billion, leaving $933.1 million available under that program.

Hidden risk.The most material tension is between reported earnings and cash. Operating cash flow fell to $369 million in 2025 from $1.19 billion in 2024, a decline of about 69%, and operating cash flow equaled only 0.24 times net income in 2025. Net income in 2025 was more than triple the 2024 figure, so the profit gain is not showing up in operating cash. Long-term debt dropped to $5.04 billion from $7.81 billion, and equity rose to $5.05 billion from $2.96 billion, but the excerpts provided do not explain these balance-sheet shifts. Readers may want to look at the cash flow statement and the reconciliation of net income to operating cash flow in the full 10-K.